Francesco Hofmann

TL;DR: The data suggest that feedback down-regulation of receptor tyrosine kinase signaling is a frequent event in tumor cells with constitutive mTOR activation, and reversal of this feedback loop by rapamycin may attenuate its therapeutic effects, whereas combination therapy that ablates mTOR function and prevents Akt activation may have improved antitumor activity.

TL;DR: The results suggest that PCTs may represent a more accurate approach than cell line models for assessing the clinical potential of some therapeutic modalities and could potentially improve preclinical evaluation of treatmentmodalities and enhance the ability to predict clinical trial responses.

TL;DR: A novel compound with therapeutic potential for the treatment of solid tumors and other diseases where angiogenesis plays an important role, PTK787/ZK 222584 is very well tolerated and does not impair wound healing.

TL;DR: NVP-ADW742 monotherapy or its combination with cytotoxic chemotherapy had significant antitumor activity in an orthotopic xenograft MM model, providing in vivo proof of principle for therapeutic use of selective IGF-1R inhibitors in cancer.

TL;DR: NVP-AEW541 represents a class of selective, small molecule IGF-IR kinase inhibitors with proven in vivo antitumor activity and potential therapeutic application and abrogates IGF-I-mediated survival and colony formation in soft agar at concentrations that are consistent with inhibition of IGF-ir autophosphorylation.